Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Markus Muenz"'
Autor:
Brian Belmontes, Rajkumar Noubade, Sarah A. O’Brien, Hayley Ma, Jason DeVoss, Benjamin M. Alba, Hong Tan, Jason Eng, Melissa Thomas, Kevin Cook, Deepali V. Sawant, Peng Li, Matthew Chun, Jackson G. Egen, Wendy Zhong, Anupurna Kaul, Famke Aeffner, Olivier Nolan-Stevaux, Xiaoting Wang, Markus Muenz
Publikováno v:
Science Translational Medicine. 13
Therapeutic approaches are needed to promote T cell-mediated destruction of poorly immunogenic, "cold" tumors typically associated with minimal response to immune checkpoint blockade (ICB) therapy. Bispecific T cell engager (BiTE) molecules induce re
Autor:
Rebecca Goldstein, Christine Karbowski, Anja Henn, Petra Deegen, Joachim Wahl, Katja Matthes, Christoph Dahlhoff, Brooke Rock, Sabrina Benchaar, Katie Hsu, Brandy Alexander, Matthias Friedrich, Joan Lane, Xiaoting Wang, Jonas Anlahr, Markus Muenz, Tobias Raum, Tara L. Arvedson
Publikováno v:
Cancer Research. 82:6313-6313
Acute myeloid leukemia is a grievous illness. BiTE® (bispecific T cell engager) molecules redirect T cells by engaging CD3 and a tumor-associated antigen (TAA). These molecules have shown clinical efficacy but one mechanism of resistance is loss of
Autor:
Ines Ullrich, Oliver Thomas, Markus Muenz, Benno Rattel, Mercedesz Balazs, Julie M. Bailis, Joachim Wahl, Alexander Sternjak, Fei Lee, Grit Lorenczewski, Matthias Friedrich
Publikováno v:
Molecular cancer therapeutics. 20(5)
AMG 596 is a bispecific T-cell engager (BiTE) immuno-oncology therapy in clinical development for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with limited therapeutic options. AMG 596 is composed of two s
Autor:
Silvana K. Rampini, Patrick A. Baeuerle, Markus Muenz, Christina K. S. Mueller, Tobias Raum, Renier Myburgh, Erika Schlaepfer, Mary-Aude Rochat, Johannes Brozy, Roberto F. Speck, Peter Kufer
Publikováno v:
Journal of Virology. 92
Today's gold standard in HIV therapy is combined antiretroviral therapy (cART). It requires strict adherence by patients and lifelong medication, which can lower the viral load below detection limits and prevent HIV-associated immunodeficiency but ca
Autor:
Karen Rex, Joachim Wahl, Peter Kufer, Kevin Graham, Mercedesz Balazs, Oliver Thomas, Angela Coxon, Roman Kischel, Tobias Raum, Matthias Friedrich, Anja Henn, Patrick Hoffmann, Pamela Bogner, Kurt Black, Tara Arvedson, Markus Muenz, Ralf Lutterbuese, Andreas Wolf, Benno Rattel, Dan A. Rock
Publikováno v:
Cancer Research. 77:55-55
T cell engaging bispecific antibody constructs (BiTE®), such as blinatumomab which targets CD19-positive cells, have shown great promise for treating certain CD19-positive hematological malignancies. Blinatumomab comprises a single chain Fv (scFv) t
Publikováno v:
Cancer Research. 73:4734-4734
BiTE antibodies are single-chain bispecific antibody constructs with dual specificity for CD3 on T cells and a surface antigen on target cells. They are capable of temporarily mounting a polyclonal T cell response that is not restricted by T cell rec